No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

Nektar completed enrollment for its Phase 2b trials of Respegg in atopic dermatitis and alopecia areata ... the standard of care drug is whether they’re Dupixent or even the JAK inhibitors and so on.

In addition to a greater risk for serious infection, patients with atopic dermatitis initiating JAK inhibitors vs Th2 cytokine inhibitors had a greater risk of Candida infections and a slightly ...

This study aims to identify potential target genes and therapeutic drugs for alopecia areata (AA). Methods: Utilizing training and testing data, we evaluated multi-gene panels derived from commonly ...

In Europe, there is an oral JAK inhibitor called Bbricitinib, which is approved by the EMA for atopic dermatitis, moderate to severe, but approved in the United States for alopecia areata ...

In addition to a greater risk for serious infection, patients with atopic dermatitis initiating JAK inhibitors vs Th2 cytokine inhibitors had a greater risk of Candida infections and a slightly ...

More information: Raajit K. Rampal et al, Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial, Nature Medicine (2025). DOI: 10.1038/s41591-025-03572-3 ...

HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable, according to a study ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of the American Academy of Dermatology ...

Adolescents with severe or very severe alopecia areata (AA) were able to regrow hair, some with a 90% improvement in hair loss, after taking the Janus kinase inhibitor baricitinib daily ...